Astellas and Teva reach US settlement over generic Vesicare
This article was originally published in Scrip
Executive Summary
Astellas and Teva Pharmaceutical Industries have agreed to settle litigation concerning a US patent for Astellas's overactive bladder drug, Vesicare (solifenacin succinate).